00:33 , Sep 28, 2018 |  BC Innovations  |  Targets & Mechanisms

Cell metabolism’s migration

As cancer metabolism undergoes a renaissance in the clinic, with compounds targeting growth factor and nutrient sensing pathways, basic research on metabolic processes in all cells is shining light on pathways that could yield new...
07:00 , Oct 13, 2014 |  BC Week In Review  |  Company News

London Health Sciences Centre, Novare deal

London Health Sciences Centre granted newco Novare rights to therapeutic products that modulate the hyaluronan-mediated motility receptor ( RHAMM ; CD168 ). RHAMM regulates stem cell production and cell movement. Novare said potential therapeutic applications...
01:42 , Oct 8, 2014 |  BC Extra  |  Company News

Allied Minds launches Novare Pharmaceuticals

Allied Minds plc (LSE:ALM) has launched Novare Pharmaceuticals (Boston, Mass.), a newco aimed at developing hyaluronan-mediated motility receptor ( RHAMM ) modulators. The company was previously an Allied Minds subsidiary known as ProGDerm Inc. RHAMM...
07:00 , May 15, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Hyaluronan-mediated motility receptor (RHAMM; CD168) Human samples and mouse studies suggest inhibiting RHAMM could help treat glioblastoma. Analysis of human glioma samples revealed...
07:00 , May 4, 1998 |  BC Week In Review  |  Company News

Hyal other research news

Research published in Clinical Cancer Research described the role of RHAMM, a receptor on tumor cells that binds hyaluronic acid. RHAMM is present in excess in breast cancer cells, and may be an indicator of...